Aviva
ADMA icon

Aviva’s ADMA Biologics ADMA Stock Holding History

Aviva’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,686
Closed -$258K – 858
2026
Q1 		$258K Buy
28,686
+1,685
+6% +$26.6K ﹤0.01% 836
2025
Q4 		$492K Sell
27,001
-2,612
-9% -$44K ﹤0.01% 770
2025
Q3 		$434K Buy
29,613
+5,492
+23% +$94.1K ﹤0.01% 839
2025
Q2 		$439K Sell
24,121
-11,385
-32% -$232K ﹤0.01% 837
2025
Q1 		$704K Buy
35,506
+4,079
+13% +$70.5K ﹤0.01% 641
2024
Q4 		$539K Buy
+31,427
New +$591K ﹤0.01% 807

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aviva's ADMA Position: Q2 2026 in Review

Aviva sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 28,686 shares — an estimated $258K sold.

Aviva first reported a position in ADMA in Q4 2024 and held it in 6 quarters. The position peaked at $704K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Aviva reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Aviva sold 28,686 ADMA Biologics shares in Q2 2026, an estimated $258K.
  • Aviva first reported a position in ADMA Biologics in Q4 2024 and held it in 6 quarters.
  • Aviva's ADMA Biologics position peaked at $704K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.